The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Approaches to first relapse in multiple myeloma in the current landscape: advice for clinicians
Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, discusses the shift in approach to treating first relapse in multiple myeloma. Prof. Lonial highlights the importance of understanding patient needs and perspectives, as well as the latest data on treatments such as CAR T-cells, bispecific antibodies, and CELMoDs, to craft an optimal individualized treatment plan. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
